Biology subjects

Firth, H.

Publications and source records attributed to Firth, H..

4 recordsLinked to original sources

bioRxiv2026

Using somatic data to aid germline clinical variant interpretation in developmental disorders

Accurate interpretation of rare germline variants remains a major challenge in developmental disorders (DD). Somatic mutation data represent a largely untapped source of evidence for germline variant classi-fication. Identical or nearby mutations that drive positive selection when present in somatic tissues can cause developmental disorders when present in the germline. We integrated somatic mutation data from the Catalogue Of Somatic Mutations In Cancer (COSMIC), and healthy tissues (sperm and buccal epithelium) with germline variant datasets from ClinVar and large studies of de novo mutations in DD patients. Across 970 dominant DD genes, 195 have evidence of somatic selection, with a majority demonstrating concordant mechanisms between germline and somatic contexts. We benchmark the ability of somatic data to discriminate pathogenic from benign germline missense variation across dominant DD genes, identifying 145 genes in which somatic data are informative. The strongest utility is in altered-function genes where germline and somatic mechanisms are concordant, for example the RASopathy genes. In these genes, codon-level aggregation of somatic missense counts yields predictive performance comparable to computational predictors or MAVE assays (AUC-ROC 0.895 for somatic data, versus 0.893 for REVEL). Combining somatic features with computational scores improves discrimination further. Using likelihood ratios, we map COSMIC missense codon count thresholds onto American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP)-style evidence strengths, showing that somatic data can reach strong levels of evidence in germline variant interpretation in DD and enable reclassification of variants of uncertain significance. Together, these results establish somatic mutation data as a scalable and clinically actionable evidence source for germline variant interpretation in select DD genes. Graphical abstract(Generated using FigureLabs) O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=104 SRC="FIGDIR/small/732808v1_ufig1.gif" ALT="Figure 1"> View larger version (40K): org.highwire.dtl.DTLVardef@1d65659org.highwire.dtl.DTLVardef@beff70org.highwire.dtl.DTLVardef@174396dorg.highwire.dtl.DTLVardef@1662b08_HPS_FORMAT_FIGEXP M_FIG C_FIG

genomics↗

bioRxiv2024

Deciphering the role of germline complex de novo structural variations in rare disorders

De novo structural variants (dnSVs) have emerged as crucial genetic factors in the context of rare disorders. However, these variations often go undiagnosed in routine genetic screening practices. To shed light on their significance in rare disease, we conducted a comprehensive analysis of the largest cohort of parent-offspring whole-genome sequencing data from the UK 100,000 Genomes Project. Our study encompassed a vast cohort of 12,568 families, including 13,702 offspring affected by rare genetic diseases. We identified a total of 1,872 dnSVs, revealing that approximately 12% of the probands harboured at least one dnSV, of which 9% were identified as likely pathogenic in affected probands (151/1696). Advanced parents age was found to be associated with an increased chance of having dnSVs in probands. We discovered 148 clustered breakpoints resulting from a single event. 60% of these complex dnSVs were classified into 9 major SV types, and could be observed in multiple individuals, while the remaining 40% were private events and had not been previously reported. We found 12% of pathogenic dnSVs are complex SVs, emphasising the critical importance of thoroughly examining and considering complex dnSVs in the context of rare disorders. Furthermore, we discovered an enrichment of maternal dnSVs at subtelometric, early-replicating regions of chromosome 16, suggesting possible sex-specific mechanisms in generation of dnSVs. This study sheds light on the extent of diversity of dnSVs in the germline and their contribution to rare genetic disorders.

genomics↗

bioRxiv2022

A human embryonic limb cell atlas resolved in space and time

Human limbs emerge during the fourth post-conception week as mesenchymal buds which develop into fully-formed limbs over the subsequent months. Limb development is orchestrated by numerous temporally and spatially restricted gene expression programmes, making congenital alterations in phenotype common. Decades of work with model organisms has outlined the fundamental processes underlying vertebrate limb development, but an in-depth characterisation of this process in humans has yet to be performed. Here we detail the development of the human embryonic limb across space and time, using both single-cell and spatial transcriptomics. We demonstrate extensive diversification of cells, progressing from a restricted number of multipotent progenitors to myriad mature cell states, and identify several novel cell populations, including neural fibroblasts and multiple distinct mesenchymal states. We uncover two waves of human muscle development, each characterised by different cell states regulated by separate gene expression programmes. We identify musculin (MSC) as a key transcriptional repressor maintaining muscle stem cell identity and validate this by performing MSC knock down in human embryonic myoblasts, which results in significant upregulation of late myogenic genes. Through integration of multiple anatomically continuous spatial transcriptomic samples, we spatially map single-cell clusters across a sagittal section of a whole fetal hindlimb. We reveal a clear anatomical segregation between genes linked to brachydactyly and polysyndactyly, and uncover transcriptionally and spatially distinct populations of mesenchyme in the autopod. Finally, we perform scRNA-seq on murine embryonic limbs to facilitate cross-species developmental comparison at single-cell resolution, finding substantial homology between the two species.

developmental biology↗

bioRxiv2021

Genetic and pharmacological causes of germline hypermutation

Mutation in the germline is the source of all evolutionary genetic variation and a cause of genetic disease. Previous studies have shown parental age to be the primary determinant of the number of new germline mutations seen in an individuals genome. Here we analysed the genome-wide sequences of 21,879 families with rare genetic diseases and identified 12 hypermutated individuals with between two and seven times more de novo single nucleotide variants (dnSNVs) than expected. In most of these families (8/12) the excess mutations could be attributed to the father. We determined that two of these families had genetic drivers of germline hypermutation, with the fathers carrying damaging genetic variation in known DNA repair genes, causing distinctive mutational signatures. For five families, by analysing clinical records and mutational signatures, we determined that paternal exposure to chemotherapeutic agents prior to conception was a key driver of hypermutation. Our results suggest that the germline is well protected from mutagenic effects, hypermutation is rare and relatively modest in degree and that most hypermutated individuals will not have a genetic disease.

genomics↗